Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 3;19(3):1797–1805. doi: 10.3892/etm.2020.8418

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — miR-103a-3p expression levels are increased in patients with cisplatin-resistant NSCLC. The level of miR-103a-3p was significantly increased in (A) the serum and (B) the tumors of patients with NSCLC that acquired resistance to cisplatin treatment compared with cisplatin-sensitive patients. (C) The level of miR-103a-3p was significantly increased in the cisplatin resistant cell line, A549/cisplatin, compared with the cisplatin-sensitive cell line, A549. (D) The level of miR-103a-3p was significantly increased in cisplatin resistant cell line, PC-9/cisplatin, compared with the cisplatin-sensitive cell line, PC-9. The levels of miR-103a-3p were assessed using reverse transcription-quantitative PCR. *P<0.05 and **P<0.01 with comparisons indicated by lines. miR, microRNA; NSCLC, non-small cell lung carcinoma; cDDP, cisplatin.